Teva Pharmaceuticals
TEVA
836 hedge funds and large institutions have $32.1B invested in Teva Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 305 increasing their positions, 316 reducing their positions, and 101 closing their positions.
44% more call options, than puts
Call options by funds: $714M | Put options by funds: $494M
3% less repeat investments, than reductions
Existing positions increased: 305 | Existing positions reduced: 316
1.47% less ownership
Funds ownership: 60.12% → 58.65% (-1.5%)
5% less funds holding
Funds holding: 876 → 836 (-40)
20% less capital invested
Capital invested by funds: $40B → $32.1B (-$7.93B)
31% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 101
39% less funds holding in top 10
Funds holding in top 10: 87 → 53 (-34)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$465M |
| 2 |
Nordea Investment Management
Stockholm,
Sweden
|
+$337M |
| 3 |
SC
Sculptor Capital
New York
|
+$287M |
| 4 |
Bank of New York Mellon
New York
|
+$220M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$154M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$434M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$243M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$194M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$187M |
| 5 |
First Eagle Investment Management
New York
|
-$144M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWM
926
Gupta Wealth Management
San Diego,
California
| – | -$23K | -357 | Closed |
|
|
TIM
927
Tortoise Investment Management
White Plains,
New York
| – | -$22K | -338 | Closed |
|
|
CFN
928
Cordasco Financial Network
Naples,
Florida
| – | -$13K | -200 | Closed |
|
|
JGIA
929
Jackson Grant Investment Advisers
Stamford,
Connecticut
| – | -$13K | -200 | Closed |
|
|
TCCM
930
Timber Creek Capital Management
Boston,
Massachusetts
| – | -$13K | -200 | Closed |
|
|
AIA
931
Allegis Investment Advisors
Idaho Falls,
Idaho
| – | -$11K | -173 | Closed |
|
932
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$9K | -136 | Closed |
|
|
BAM
933
Barrett Asset Management
New York
| – | -$7K | -109 | Closed |
|
|
HA
934
Harfst & Associates
Sheridan,
Wyoming
| – | -$6K | -100 | Closed |
|
|
LWA
935
Lenox Wealth Advisors
New York
| – | -$6K | -93 | Closed |
|
|
KC
936
Kingfisher Capital
Charlotte,
North Carolina
| – | -$6K | -90 | Closed |
|
|
ADL
937
Asset Dedication LLC
San Francisco,
California
| – | -$4.63K | -79 | -92% |
|
TEVA Hedge Fund Activity: Q1 2016 in Review
836 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2016, worth a combined $32.1B — down 20% from $40B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of TEVA and 70 opened new positions — a net loss of 31 holders — while 316 trimmed existing stakes and 305 added.
The largest buyer was Viking Global Investors, adding an estimated $465M. The largest seller was Fidelity Investments, cutting an estimated $434M.
- 836 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2016, down from 876 in Q4 2015.
- Funds reported $32.1B of Teva Pharmaceuticals stock for Q1 2016, down 20% quarter-over-quarter.
- 70 funds opened new Teva Pharmaceuticals positions in Q1 2016 and 101 closed out, a net change of -31 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2016 was Viking Global Investors, an estimated $465M added.
- The largest Teva Pharmaceuticals seller in Q1 2016 was Fidelity Investments, an estimated $434M sold.
Based on aggregated 13F filings for Q1 2016.